Objective: The current meta-analysis evaluated the association between vitamin B 12 intake and blood vitamin B 12 level and colorectal cancer (CRC) risk. Design: The PubMed and EMBASE databases were searched. A dose-response analysis was performed with generalized least squares regression, with the relative risk (RR) and 95 % CI as effect values. Setting: The meta-analysis included seventeen studies. Subjects: A total of 10 601 patients. Results: The non-linear dose-response relationship between total vitamin B 12 intake and CRC risk was insignificant (P = 0·690), but the relationship between dietary vitamin B 12 intake and CRC risk was significant (P < 0·001). Every 4·5 μg/d increment in total and dietary vitamin B 12 intake was inversely associated with CRC risk (total intake: RR = 0·963; 95 % CI 0·928, 0·999; dietary intake: RR = 0·914; 95 % CI 0·856, 0·977). The inverse association between vitamin B 12 intake and CRC risk was also significant when vitamin B 12 intake was over a dosage threshold, enhancing the non-linear relationship. The non-linear dose-response relationship between blood vitamin B 12 level and CRC risk was insignificant (P = 0·219). There was an insignificant association between every 150 pmol/l increment in blood vitamin B 12 level and CRC risk (RR = 1·023; 95 % CI 0·881, 1·187). Conclusions: Our meta-analysis indicates that evidence supports the use of vitamin B 12 for cancer prevention, especially among populations with high-dose vitamin B 12 intake, and that the association between CRC risk and total vitamin B 12 intake is stronger than between CRC risk and dietary vitamin B 12 intake only.
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide (1) . The development of CRC in the normal colorectal epithelium results from genetic alterations, epigenetic modifications and environmental factors (2) (3) (4) . Diet may be an important aetiological factor in CRC (5) and several biological mechanisms may explain the relationship between diet and CRC risk (5) .
Vitamin B 12 is an essential coenzyme for methionine synthase, which maintains adequate intracellular methionine levels in one-carbon metabolism (6, 7) for several intracellular biological processes, including methylation reactions, nucleotide biosynthesis and DNA repair (8) . Recent studies have shown that one-carbon metabolism may be related to colorectal carcinogenesis (9, 10) . Therefore, vitamin B 12 deficiency may increase CRC risk (11, 12) . However, several studies have reported that vitamin B 12 is not associated with the risk of CRC (13, 14) , or that folic acid plus vitamin B 12 is associated with increased cancer risk (15) .
The results on the association between vitamin B 12 intake and CRC risk are still controversial and no relevant pooled analyses have been performed. Therefore the aim of our meta-analysis study was to quantitatively and comprehensively summarize whether vitamin B 12 intake or blood vitamin B 12 level is related to CRC risk.
Methods

Literature search
A literature search for relevant studies was performed using the PubMed and EMBASE databases up to April 2014.
The search terms used were: (vitamin B 12 OR cyanocobalamin OR cobalamins OR cobalamin OR hydroxocobalamin OR 5′-deoxyadenosyl cobalamin) AND (colorectal cancer OR colon cancer OR rectal cancer). Moreover, we manually screened the references of the relevant studies and reviews to check for other potentially relevant studies.
Eligibility criteria
The studies which met the following eligible criteria were included: (i) cohort study or case-control study; (ii) the exposure of interest was vitamin B 12 intake, or blood vitamin B 12 level, for three or more quantitative categorized levels; (iii) the outcome of interest was related to CRC; and (iv) the risk estimates (OR, risk ratio (RR) or hazard ratio (HR)) and corresponding 95 % CI were reported or calculated from published data with a category-specific number of cases and a category-specific number of either person-years or non-cases. When several studies were based on the same population, only the most informative study was included.
Data extraction and quality assessment Data were independently extracted by two reviewers. For each study, the following data were extracted: first author, publication year, publication country, study design, study name, population characteristics (sex and age), follow-up period, sample size, type of vitamin B 12 intake (total intake = dietary intake plus dietary supplements; dietary intake; supplemental intake), measures and ranges of exposure, adjusted variables, and risk estimates with corresponding 95 % CI for each category. Risk estimates that reflected the greatest degree of adjustment for potential confounders were extracted.
The quality of the included studies was assessed according to the Newcastle-Ottawa Scale criteria (16) . A funnel plot was used to assess publication bias. Any disagreement on the data extraction and quality assessment of the studies was resolved through comprehensive discussion.
Statistical analysis
A dose-response analysis was first utilized to assess the relationship between vitamin B 12 intake and blood vitamin B 12 level and CRC risk using the generalized least squares method because this method can resolve the problem that the included studies used different FFQ (17, 18) . The analytical method required the distribution of case and person-years, median values of vitamin B 12 intake or blood vitamin B 12 levels, and corresponding risk estimates in each category for each study. If there were results on both dietary and total B 12 intake in one study, we used the results on total vitamin B 12 intake for the main analyses. For each study, the mean or median value of vitamin B 12 intake and blood vitamin B 12 level in each category was assigned to each corresponding risk estimate. The assigned value of the lowest category was designated as a reference level. If the study did not provide mean or median values of exposure, the midpoint of the upper and lower boundaries in each category was assigned the median value of exposure (19) . For the openended exposure categories, the length of the open-ended interval was assumed to be the same as that of the adjacent interval (20) .
We used random-effect restricted cubic splines with three knots at the 25 %, 50 % and 75 % percentiles of the distribution to examine a potential non-linear doseresponse relationship between vitamin B 12 intake and blood vitamin B 12 level with CRC risk (21, 22) . A P value for non-linearity was calculated by testing the null hypothesis that the regression coefficient of the second spline was equal to zero (21) . To test and verify the non-linear model, a meta-analysis comparing the appropriate open categories (or highest category) of exposure with the lowest category was performed. The non-linear dose-response relationship was also verified by several representative point values and the risk estimates of a subgroup analysis based on the range of exposure.
RR was used as a measure of the association between exposure and CRC risk. The OR provided by a casecontrol study was used as an estimate of the RR because the incidence of CRC was sufficiently rare (23) . When the category-specific risk estimates were reported separately for different polymorphisms in the 5,10-methylenetetrahydrofolate reductase gene, we combined the multiple risk estimates into a pooled estimate using a fixed-effects model for further meta-analysis (24) . When the RR of different population databases or population sex were presented in one study, we considered each population database as one study.
The heterogeneity of the studies was evaluated using the Cochran Q test and the I 2 statistic (25) . A P value <0·10 for the Q statistic and/or I 2 > 50 % were considered to indicate statistically significant heterogeneity. The randomeffects model was then used if there was significant heterogeneity; otherwise, the fixed-effects model was used. A subgroup analysis and a Galbraith plot were used to explore the sources of heterogeneity. Publication bias was evaluated with Egger's and Begg's tests (26, 27) , and a trim-and-fill analysis was conducted if publication bias was detected (28) . To explore the association between sample size and the RR for CRC, we constructed a sampling-based scatter plot graphically summarizing the association by modelling sample size as a continuous variable. A subgroup analysis was performed based on sample size. We also conducted subgroup analyses stratified by geographic region, type of vitamin B 12 taken, range of exposure and tumour site.
A two-sided P value <0·05 was considered statistical significance. All statistical analyses were conducted using the statistical software package Stata version 12·0. Figure 1 shows a detailed flowchart of the literature search and the study inclusion procedure. A total of 1362 studies were initially identified with this literature search, but 1231 studies were excluded after screening the titles and abstracts. Then 114 studies were excluded after a full text review. Finally, fourteen studies of vitamin B 12 intake and three studies of blood vitamin B 12 level were identified as eligible for our meta-analysis.
Results
Selection of studies
Study characteristics
The fourteen studies of vitamin B 12 intake included a total of 9693 cases (Table 1) (11) (12) (13) (14) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . The studies were conducted in Asia, Europe and North America, and were published between 2008 and 2013. In terms of the study design, five studies were cohort studies (13, 29, 31, 34, 36) and nine studies were case-control studies. Of these fourteen studies, eight studies provided results only for dietary vitamin B 12 intake from food (11, (30) (31) (32) (33) (34) 37, 38) , three studies provided results only for total vitamin B 12 ( 13, 35, 36) , and three studies provided both total and dietary vitamin B 12 intakes (12, 14, 29) . Besides the main end point of CRC, six studies provided sub-cohort results for colon cancer and/or rectal cancer separately (11, 13, 14, 31, 32, 36) . Three case-control studies on blood vitamin B 12 levels were conducted in the USA and Sweden, and were published between 2008 and 2010, comprising a total of 908 cases and 2387 controls ( Table 2) (39) (40) (41) .
Dose-response association between vitamin B 12 intake and colorectal cancer risk
We first evaluated the non-linear dose-response relationship between vitamin B 12 intake and CRC risk. Heterogeneity existed (P heterogeneity = 0·017) in the overall analysis of vitamin B 12 intake, with a significant non-linear dose-response relationship (P non-linearity = 0·026; Fig. 2 ). In the non-linear dose-response relationship, there was a slight trend towards a reduction in CRC risk when vitamin B 12 intake was less than 12·85 μg/d, although the reduction was not statistically significant, and a significantly reduced risk was observed when vitamin B 12 intake was more than 12·85 μg/d. A slight reduction in CRC risk was also observed with every 4·5 μg/d increment in vitamin B 12 intake (RR = 0·961; 95 % CI 0·930, 0·994) when we evaluated the relationship in a separate analysis with a linear model, suggesting that similar trends were observed with linear and non-linear models.
In addition, dose-response analyses for the association between vitamin B 12 intake and CRC risk were stratified based on the type of vitamin B 12 intake (total intake and dietary intake). There was no evidence of a non-linear association between total vitamin B 12 intake and CRC risk (P non-linearity = 0·690), and every 4·5 μg/d increment in total vitamin B 12 intake was inversely associated with CRC risk (RR = 0·963; 95 % CI 0·928, 0·999) without significant heterogeneity (P heterogeneity = 0·138). For dietary vitamin B 12 intake there was significant evidence of non-linearity, and every 4·5 μg/d increment in dietary vitamin B 12 intake was inversely associated with CRC risk (RR = 0·914; 95 % CI 0·856, 0·977) under the linear model.
The non-linear dose-response relationship ( Fig. 2 ) graphically showed that vitamin B 12 intake above a certain threshold (high dose, i.e. >12 μg/d) was inversely associated with CRC risk. We used several representative point values to test and verify the non-linear dose-response relationship by pooling the CRC risks for appropriate open categories of vitamin B 12 intake when the lowest category in each study was regarded as a reference level. Our results indicated a significantly decreased risk of CRC when the vitamin B 12 intake was above a certain threshold (8·5 μg/d: RR = 0·898; 95 % CI 0·824, 0·979; 11 μg/d: RR = 0·843; 95 % CI 0·731, 0·971; or 13 μg/d: RR = 0·881; 95 % CI 0·802, 0·968), thereby enhancing the non-linear doseresponse relationship.
Dose-response association between blood vitamin B 12 level and colorectal cancer risk
There was no heterogeneity (P heterogeneity = 0·327) in the overall analysis of blood vitamin B 12 between blood vitamin B 12 level and CRC risk (P non-linearity = 0·219). The results of the linear model indicated that every 150 pmol/l increment in blood vitamin B 12 level was not associated with CRC risk (RR = 1·023; 95 % CI 0·881, 1·187) without significant heterogeneity (P heterogeneity = 0·303).
High v. low vitamin B 12 intake or blood vitamin B 12 level
In the crude analyses, the highest vitamin B 12 intake or blood vitamin B 12 level v. the lowest intake or blood level was insignificantly associated with CRC risk (vitamin B 12 intake: RR = 0·942; 95 % CI 0·829, 1·070; blood vitamin B 12 level: RR = 0·927; 95 % CI 0·560, 1·534). We also performed in-depth subgroup analysis of the vitamin B 12 intake. The results indicated that the association between vitamin B 12 intake and CRC risk was stronger in studies with a wider range of vitamin B 12 intake (>8 μg/d difference in assigned value compared with the reference level: RR = 0·831; 95 % CI 0·711, 0·971; Fig. 3 ) compared with studies with a narrower range of vitamin B 12 intake (≤8 μg/d: RR = 1·016; 95 % CI 0·878, 1·175), thereby enhancing the non-linear doseresponse relationship. The highest v. lowest total vitamin B 12 intake was significantly associated with CRC risk (RR = 0·870; 95 % CI 0·782, 0·967). The association between sample size and the RR of CRC is summarized in Fig. 4 with a sampling-based scatter plot. The subgroup analysis based on sample size showed that the sample sizes of the studies did not obviously influence our results. Detailed subgroup analyses based on CRC sites, sex of participants, regions of participants and the adjusted covariates were also conducted, and the results are summarized in Table 3 .
Publication bias
Begg's test and Egger's test showed no evidence of publication bias for the overall analysis of vitamin B 12 intake (P Begg = 0·192, P Egger = 0·266) and blood vitamin B 12 level (P Begg = 1·000, P Egger = 0·447), and the subgroup analysis of total vitamin B 12 intake (P Begg = 0·348, P Egger = 0·616).
Discussion
The one-carbon metabolism pathway requires adequate vitamin B 12 and this raises the possibility that vitamin B 12 may have an important role in CRC risk. However, the association between vitamin B 12 and CRC risk is still under debate due to a lack of sufficient evidence. To the best of our knowledge, our present dose-response meta-analysis is the first study to systematically evaluate the association between vitamin B 12 and CRC risk.
In crude overall analyses, vitamin B 12 intake or blood vitamin B 12 level was insignificantly associated with CRC risk. Interestingly, current results found a non-linear dose-response relationship between vitamin B 12 intake and CRC risk. The association was insignificant if vitamin B 12 intake was under a certain threshold (low dosage, i.e. <7 μg/d), whereas vitamin B 12 intake above a certain threshold (high dosage, i.e. >12 μg/d) was inversely associated with CRC risk. Moreover, this nonlinear dose-response relationship was enhanced by several representative point values and the risk estimates of subgroup analysis based on range of exposure (Fig. 3) .
The biological mechanisms responsible for the protective effect of high-dosage vitamin B 12 are unclear. One possible explanation is that vitamin B 12 is an essential (42) . Furthermore, B-group vitamin supplementation, including vitamin B 12 , may have antioxidant and anti-inflammatory effects (43, 44) . In addition, animal experiments have shown that vitamin B 12 can inhibit the proliferation of cancer cells (45) . We did not find statistically significant evidence for a non-linear relationship between blood vitamin B 12 (14) Williams et al. (2010) (12) (AA) Zschabitz et al. (2013) (29) Sample size (×1000) Fig. 4 The association between sample size and the relative risk (RR) of colorectal cancer; a sampling-based scatter plot summarized the association between sample size and the RR of colorectal cancer increment in blood vitamin B 12 level was not associated with CRC risk, enhanced by the analysis of the highest blood vitamin B 12 levels v. lowest blood levels. One explanation may be that all included studies roughly assessed blood vitamin B 12 level in relation to CRC risk while ignoring the fact that only methylcobalamin and 5′-deoxyadenosylcobalamin are the principal active coenzyme forms of vitamin B 12 compared with other forms of vitamin B 12 in blood (e.g. cyanocobalamin and hydroxocobalamin) (46) (47) (48) . Thus, these inactive forms of blood vitamin B 12 may underestimate the effect of active forms of vitamin B 12 on CRC risk. Similar to studies regarding pyridoxal 5′-phosphate (PLP, the active form of vitamin B 6 ), the association between the active forms of vitamin B 12 and CRC risk should be deeply investigated by further multicentre clinical studies. Our meta-analysis indicated no association between blood vitamin B 12 level and CRC risk, different from the association found between vitamin B 12 intake and CRC risk. One potential reason may be that plasma vitamin B 12 level has been found to be only slightly correlated with dietary vitamin B 12 intake (multivariable Pearson correlation coefficient, r = 0·08) and total vitamin B 12 intake (r = 0·25) (49) .
The strength of the current meta-analysis study was that our results and conclusions were enhanced by an in-depth subgroup analysis. A subgroup analysis based on the type of vitamin B 12 intake indicated that the association between total vitamin B 12 and CRC risk was stronger than the association between dietary vitamin B 12 intake alone and CRC risk ( Table 3 ). As expected, heterogeneity was reduced to low levels in the assessment of total vitamin B 12 intake. Supplemental vitamin B 12 intake may play an important role in CRC risk, and Zschabitz et al. showed that supplemental vitamin B 12 intake was marginally associated with CRC risk (29) . However, the interaction between supplemental vitamin B 12 intake and dietary vitamin B 12 intake is unclear. Thus, the type of vitamin B 12 intake may be important for the assessment of vitamin B 12 intake and CRC risk, and future clinical studies should not ignore the role of supplemental vitamin B 12 intake. The association between vitamin B 12 intake and CRC risk may be various among different races of population (Table 3) , in agreement with the study by Williams et al. in which the associations between vitamin B 12 and distal CRC differed for whites compared with African Americans (12) . This may be due to polymorphisms in genes related to one-carbon metabolism, supported by a previous study in which gene-nutrient interactions in folate-mediated one-carbon metabolism played an important role in modifying the risk of CRC (32) . No evidence of publication bias was detected, indicating that the entire pooled results may be unbiased.
Several limitations of our meta-analysis must be acknowledged. First, the controls were not always of uniform ascertainment in case-control studies, although most studies matched controls to cases based on age and sex. Some controls might therefore have had benign diseases or other risk factors that contribute to CRC risk and misclassifications of controls or vitamin B 12 intake possibly exist among several included studies. Second, some important confounding factors were not measured in several studies and some inherently confounding factors in included studies could not be solved perfectly in our study. Thus, an inadequate control of confounding factors may lead to an underestimation of risk estimates of vitamin B 12 on CRC. Third, the limited number of included studies may impact the statistical power and performance of some in-depth subgroup analysis. The assigned value of vitamin B 12 in each category (midpoint, mean and median) was not available in all included studies for dose-response analysis. Therefore, various assigned values might affect the accuracy of the dose-response relationship. In addition, a considerable degree of heterogeneity was observed among studies and could not be explained completely. Our subgroup analysis indicated that study design may have been one source of heterogeneity. After the case-control studies were excluded, the heterogeneity among the studies decreased (I 2 = 32·3 %) and the fixed-effects model was used. Similarly, our results also showed that the types of vitamin B 12 intake and population sex contributed to the heterogeneity (total vitamin B 12 intake group: I 2 = 22·9 %; female group: I 2 = 35·7 %). For individual studies, the result of the Galbraith plot (Fig. 5 ) indicated that the studies by Liu et al. (32) and Kune and Watson (11) contributed substantial heterogeneity. Indeed, the heterogeneity was clearly reduced after the removal of one or both of these studies . The remaining unexplained heterogeneity may have been caused by differences in the population characteristics and methodological differences (e.g. differences in the estimates of vitamin B 12 intake in FFQ and the control of confounding factors). The heterogeneity did not influence or dominate the quality or stability of the results. Despite these limitations, the present study is the first dose-response meta-analysis to quantitatively assess the association between vitamin B 12 and CRC risk.
Conclusion
In conclusion, results from the present meta-analysis indicate that vitamin B 12 intake is inversely associated with CRC risk when the dosage of vitamin B 12 intake is above a certain threshold, and that the association between total vitamin B 12 and CRC risk is stronger than the association between dietary vitamin B 12 intake alone and CRC risk. In addition, there was an insignificant association between blood vitamin B 12 level and CRC risk. Further studies are required to investigate the associations between the active forms of blood vitamin B 12 and CRC risk and to evaluate the influence of vitamin B 12 supplementation.
